Modeling and inference of spatio-temporal protein dynamics across brain
  networks by Garbarino, Sara & Lorenzi, Marco
Modeling and inference of spatio-temporal
protein dynamics across brain networks
Sara Garbarino and Marco Lorenzi
for the Alzheimer’s Disease Neuroimaging Initiative ?
EPIONE project-team, INRIA, Universite Cote d’Azur, Sophia Antipolis, France
sara.garbarino@inria.fr
Abstract. Models of misfolded proteins (MP) aim at discovering the
bio-mechanical propagation properties of neurological diseases (ND) by
identifying plausible associated dynamical systems. Solving these sys-
tems along the full disease trajectory is usually challenging, due to the
lack of a well defined time axis for the pathology. This issue is addressed
by disease progression models (DPM) where long-term progression tra-
jectories are estimated via time reparametrization of individual observa-
tions. However, due to their loose assumptions on the dynamics, DPM
do not provide insights on the bio-mechanical properties of MP propaga-
tion. Here we propose a unified model of spatio-temporal protein dynam-
ics based on the joint estimation of long-term MP dynamics and time
reparameterization of individuals observations. The model is expressed
within a Gaussian Process (GP) regression setting, where constraints on
the MP dynamics are imposed through non–linear dynamical systems.
We use stochastic variational inference on both GP and dynamical sys-
tem parameters for scalable inference and uncertainty quantification of
the trajectories. Experiments on simulated data show that our model
accurately recovers prescribed rates along graph dynamics and precisely
reconstructs the underlying progression. When applied to brain imaging
data our model allows the bio-mechanical interpretation of amyloid de-
position in Alzheimer’s disease, leading to plausible simulations of MP
propagation, and achieving accurate predictions of individual MP depo-
sition in unseen data.
Keywords: Bayesian non–parametric model · protein propagation · Alzheimer’s
disease · Gaussian process · dynamical systems · spatio–temporal model · disease
progression model.
1 Introduction
A peculiarity of neurodegenerative diseases (NDs) is the misfolding and sub-
sequent accumulation of pathological proteins in the brain, leading to cellular
? Data used in preparation of this article were obtained from the Alzheimers Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the inves-
tigators within the ADNI contributed to the design and implementation of ADNI
and/or provided data but did not participate in analysis or writing of this report.
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dysfunction, loss of synaptic connections, and neuronal loss [1]. Misfolded pro-
tein (MP) aggregates can self-propagate and spread the pathology between cells
and tissues, along functional or structural brain networks [2].
With the aim of describing such processes, a variety of mathematical mod-
els has been proposed for providing better insight into the microscopic kinetic
dynamics governing the processes of proteins propagation [3]. Complementar-
ily, another class of models relies on macroscopic measurements from molecular
and structural imaging for describing the effects of MP propagation along brain
networks [4,5,6,7,8]. Such MP kinetics models are of strategic relevance, as they
may provide new understanding of the mechanisms involved in NDs, and thus
allow identification of novel strategies for treatment and diagnosis. These mod-
els usually define the propagation dynamics through diffusion equations. This
modelling choice allows to reduce the number of parameters to be estimated,
but comes at the expenses of an oversimplification of the dynamics governing
the MP process. First, while the pathological kinetics may be assimilated to
diffusive processes in short term observations, the long term evolution of NDs
are unlikely to have diffusive properties. For example, the asymptotically con-
stant behaviour of NDs may not be described by the stationary and constant
rate of change specified by diffusion equations. Second, such models require a
precise definition of the time axis, which is typically not well defined in clinical
data sets. To address this issue, several alternative disease progression models
(DPM) have been proposed [9,10,11,12]. These approaches allow to reconstruct
biomarkers trajectories along the long term disease progression by “stitching”
together short term individual measurements. Each subject is characterized by
specific time parameters quantifying their pathological stage with respect to
the estimated global group–wise evolution. However, these models provide an
“apparent” description of biomarkers dynamics, without in fact elucidating the
kinetics and relationships across biomarkers.
To date, no modelling framework allows for joint MP kinetics modelling and
reconstruction of the biomarkers dynamics across the whole disease long term
evolution. The problem is challenging since it requires to simultaneously account
for short term observations to reconstruct the long term disease progression,
and to estimate group–wise dynamics parameters specified by high–dimensional
dynamical systems.
In this paper we solve this problem by formulating a model for the dynam-
ics of MP accumulation, clearance and propagation (ACP) across structural
brain networks, which includes data–driven estimates of the long term protein
trajectories from short term data. Figure 1 shows a schematic representation
of our framework. The ACP model is formulated as a constrained regression
problem in a Bayesian non–parametric setting, where the MP progression is
modelled by a Gaussian Process (GP), and constraints on the MP dynamics are
imposed through systems of non linear ordinary differential equations (ODEs).
The Bayesian setting allows for uncertainty quantification of the MP dynam-
ics while, to achieve tractability, the inference problem is solved via stochastic
variational inference. The constrained regression framework provides a complete
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Fig. 1. Schematic representation of our framework. Here we have two brain regions
whose MP concentrations c1 and c2 are collected for many subjects over a short term
time span (A). The dynamics of such concentrations is described in terms of the ac-
cumulation, clearance and propagation processes, with unknown parameters (B). The
proposed Bayesian framework estimates the distribution of such parameters (here plot-
ted against their ground truth values - the vertical black lines in the distributions sub-
plot), and the long term trajectories with respect to the estimated disease time axis
(C).
description of the MP dynamics, which can be subsequently used for simulat-
ing and predicting MP changes over time through forward integration of the
estimated dynamical systems. The estimated MP dynamics also provide an in-
strument to investigate different hypotheses of MP propagation.
We test our framework against synthetic data and compare its performances
in recovering the simulated evolution and the time reparameterization as com-
pared to standard disease progression models based on monotonic constraints.
Finally, we demonstrate our framework on AV45-PET data of Alzheimer’s Dis-
ease (AD) subjects from the ADNI data set. We show that it allows to compare
different hypothesis of MP kinetics: diffusive vs non–linear and time–varying dy-
namics properties (ACP). We show that the ACP model outperforms diffusive
ones in terms of prediction of amyloid deposition in unseen follow-up data.
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2 Methods
2.1 Non–linear and time–varying MP kinetics model
We consider the brain as a system of N interconnected regions, where each region
i (i = 1, ..., N) is characterized by its concentration ci(t) of MP proteins along
time. Standard MP kinetics models are based on the definition of dynamical
systems of the form
c˙(t) = βAc(t), (1)
where c(t) is the vector of concentrations of MP across brain regions, A is a dif-
fusion matrix and β is the parameter describing MP propagation. The operator
A is usually defined as the graph Laplacian of the brain connectome, while β is
typically assumed to be constant throughout the whole disease progression [4].
Here we introduce an extension of this paradigm which accounts for the dy-
namics characterized by the time–varying and non–linear parameters of MP ac-
cumulation, brain response via MP clearance, and long term propagation across
neighbouring neuronal cells: the ACP model. Within this setting, equation (1)
is reformulated as
c˙(t) = MACP (c(t))c(t), (2)
where the matrix MACP is factorized into (dependence on t is omitted but im-
plied): MACP (c) = MAC(c)−Mout(c) +Min(c). Here, MAC(c) accounts for the
total aggregation of MP plaques, i.e. sum of accumulation and clearance, while
the remaining two matrices describe long–range propagation from (Mout(c)) or
to (Min(c)) for each region. Our assumptions on the MP dynamics are the fol-
lowing:
– no aggregation nor propagation occur in healthy conditions. MP plaques
aggregation develops when the accumulation-clearance equilibrium breaks.
This can be modelled with the assumption that k¯a − k¯c > 0, where k¯· are
the maximum rates of accumulation and clearance and are assumed to be
constant across regions. We define k¯t := k¯a − k¯c as the maximum rate of
total aggregation.
– We hypothesize a region–dependent critical threshold ηi above which the
aggregation process reaches a plateau. This is modelled by a sigmoid function
kt(ci) =
k¯t
1 + el2(ci−ηi)
. (3)
– When passing a critical threshold γj the MP concentration in each region j
saturates and triggers propagation towards the connected regions. Also, it
reaches a plateau when passing a threshold ηj . Again this can be modelled
by a function asymptotically dropping to zero:
kij(cj) =
k¯ij(
1 + e−l1(cj−γj)
) (
1 + el2(cj−ηj)
) , (4)
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representing the non–linear rate of propagation from region j to region i.
Here k¯ij is the maximum rate of propagation between the two regions, and
we assume k¯ij = k¯ji. We combine the propagation coefficients in a matrix
describing the global brain–scale propagation process: K(c) = (kij(cj))ij .
– The substrate for propagation is the structural connectome, here represented
by the symmetric and normalized adjacency matrix of connections between
brain regions A = (αij).
Such assumptions are formalized into the following functionals:
(MAC(c))ij =
{
kt(c) if i = j
0 otherwise;
(5)
Min(c) = K(c)A; (6)
(Mout(c))ij =
{∑
j(K(c)ij Aij) if i = j
0 otherwise.
(7)
Overall, the ACP model depends on 1+2N+N
2−N
2 parameters: θ = (k¯t, ηi, γi, k¯ij)
for i, j = 1, ..., N .
2.2 Extending MP dynamics modelling to account for time
reparametrization
Once defined our dynamical system as the one described in (2), we need to
incorporate it within a regression framework for short term data. Let us assume
to have S subjects for which we have measures of MP concentrations C in N
brain regions at different time–points, encoded in a vector t: C is therefore the
realization of c(t) at times t. For notation simplicity we assume here t to be the
same for every subject, but computations extend easily to more general cases.
The observations C for subject k at a time points t can be modelled as a
random sample from the following generative model [10]:
Ck(t) = f(τ k(t)) + νk + . (8)
Here f is the fixed effect function modeling the concentrations’ longitudinal evo-
lution and is modelled as a GP; τ k(t) is the individual time reparametrization
with respect to the global group–wise evolution, and is modelled as a linear
shift τ k = tk + dk; νk is the individual random effect, assumed to be Gaussian
correlated perturbations N (0, φkN );  is the observational noise. We introduce
constraints on the dynamics of the model f enforcing the concentrations’ evolu-
tion to the ACP model. This means specifying a family of admissible functions
whose derivatives evaluated at the inputs t satisfy the ACP constraint:
A = {f(t) : f˙(t) = MACP (f(t))f(t)}. (9)
We note that the constraints are imposed only on the group–wise dynamics f and
not on the random–effects. This is done to reduce complexity and the model’s
parameters. Relaxing the constraints at individual level is also meaningful, as
some subjects may be characterized by potentially different dynamics due to
specific clinical conditions.
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2.3 The inference scheme
We define as F k the realization of f at τ k(t), and as F˙
k
the set of realizations of
f and of its derivatives at τ k(t). We also indicate by F , ν, and F˙ the collections
of F k, νk, and F˙
k
for all the subjects (k = 1, ..., S). Similarly, we define τ as the
collections of τ k. We denote by θ the set of parameters for the MP dynamics,
and by φN the parameters associated to ν. Our framework is formulated as the
constrained regression defined through two likelihood elements: a data fidelity
term p(C|F , φN , τ , ) and a constraint term p(A|F˙ , θ, τ , ζ), where  and ζ are
the associated noise parameters.
Following [13] we solve the constrained regression problem by determining a
lower bound for the marginal function
p(C,A|φN , τ , t, , ζ) =
∫
p(C|F , φN , τ , t, )p(A|F˙ , θ, τ , t, ζ)
p(F , F˙ |φN , τ , t)p(θ)dF dF˙ dθ,
(10)
where
p(F , F˙ |φN , τ , t)dF = p(F˙ |F )p(F |φN , τ , t). (11)
We assume the likelihood for data and constraints to be respectively Gaussian
and Student–t with parameters  and ζ [13], and we approximate the GP via
random features expansion, as shown in [14]. Specifically, the GP realizations
can be expressed as F ≈ h(tΩ)W , where Ω is a linear projection of the input t
into the random feature space specified by the trigonometric activation functions
h(·) = (cos(·), sin(·)), and W are the regression parameters. Such approximation
extends to the derivatives of the GP thanks to the chain rule [13]. As a result,
the GP function and its derivatives can be both identified by the parameters W
and Ω.
Solving (10) amounts at doing inference on F , which in this setting means
inference on W and Ω. Following [14], we optimize (10) through variational
inference of W ,Ω and θ. This leads to the optimization of the evidence lower
bound (ELBO):
log(p(C,A|φN , τ , t, , ζ)) ≥Eq(W ) [log(p(C|Ω,W , φN , τ , t, ))] +
+ Eq(W )q(θ) [log(p(A|Ω,W , θ, τ , t, ζ))] +
−DKL(q(W )|p(W ))−DKL(q(θ)|p(θ)).
(12)
Here DKL(q|p) is the Kullback Leibler divergence between p and its variational
approximation q; we assume q(W ) and q(θ) to be Gaussian. Details on the
implementation setting are in Supplementary Material.
3 Simulation Results
We test the ability of our framework in reconstructing the long term trajectories
of the ACP dynamical system from noisy samples of short term data (Figure 2).
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Results are compared to the ones obtained by using the GP Progression Model
[10], which includes a monotonicity constraints on the trajectories. We also test
the model with data generated from a single subject and with known time–axis
(Supp. Mat.). Synthetic data are generated according to the parameters spec-
ified in Table 1. Figure 2B)-top shows the reconstructed MP trajectories from
short-term data in 2A), for a two-dimensional test set. We run synthetic tests
N subjects N regions time interval time–points per subject noise
50 {2, 3, 11, 42} [0, 15] {1, 2, 3, 4} N (0, σ), 0.2 ≤ σ ≤ 0.4
k¯ij k¯t γ η
U(0, 1) U(0, 1/2) U(1,max(C
2
)) U(max(C
2
),max(C))
Table 1. Synthetic data generation parameters.
Fig. 2. Results for a 2D example data. A): ground truth GP progressions and associated
short term data used for benchmarking. B): ground truth and reconstructed (average)
long term trajectories, and reconstructed MP parameters distributions, whose ground
truth values are indicated by vertical bars.
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varying the initial values of the MP parameters, the noise and the number of
regions. Then, we compared our estimates of the GP and time-shift parameters
with results obtained using the GP Progression Model in [10]. Table 2 shows
results in terms of distributions of root mean squared errors (RMSE), for in-
creasing number of regions. Distributions of RMSE were obtained by sampling
200 times from the estimated distributions. The ACP model generally provides
better estimates for the reconstruction of the long term trajectories, as well as
for the estimation of the individual time–shift as compared to the standard DPM
provided by the monotonic GP. Moreover, while our framework allows the iden-
tification of the prescribed dynamical system parameters with high degree of
accuracy (Table 2, last row), the monotonic DPM does not allow the estimation
of these quantities.
N=2 N=3 N=11 N=42
Data fit
RMSE ACP GP 1.17(0.77) 0.93(0.37) 1.52(0.25) 1.07(0.64)
monotonic GP 1.32(0.68) 1.08(0.52) 1.60(0.29) 1.20(0.72)
Time–shift
RMSE ACP time-shift 1.67(0.49) 1.92(0.64) 1.53(0.42) 1.19(0.39)
monotonic time–shift 1.87(0.44) 1.97(0.58) 1.62(0.42) 1.20(0.41)
Dynamical parameters
relative ACP GP 6.3% 9.6% 11.4% 21.9%
error monotonic GP – – – –
Table 2. RMSE results for GP fit, time–shifts estimates and dynamical parameters
for both the GP Progression Model with monotonicity (GP) and the ACP model. The
error for the dynamical parameters is expressed, in percentage, relatively to the ground
truth parameters.
4 Modeling amyloid deposition from imaging data
4.1 Data Acquisition and Preprocessing.
ADNI data This study used 1091 individual data from ADNI, with a total of
2380 longitudinal data. We collected clinical, demographic and AV45-PET SUVr
data. All the subjects with either “Dementia”, “Mild Cognitive Impairment” or
“Cognitively Normal” clinical diagnosis were selected. The ADNI was launched
in 2003 as a public-private partnership, led by Principal Investigator Michael W.
Weiner, MD. The primary goal of ADNI has been to test whether serial Magnetic
Resonance Imaging (MRI), Positron Emission Tomography (PET), other biolog-
ical markers, and clinical and neuropsychological assessment can be combined
to measure the progression of MCI and early AD. For up-to-date information,
see www.adni-info.org. ADNI AV45-PET SUVR data are already computed on
Freesurfer–defined regions, and normalized against the reference region (cerebel-
lum); for full information please see: https://adni.bitbucket.io/reference/docs/.
We constructed a regression model for each region separately with normalized
SUVr as dependent variable and gender, age, APEO4 genotype and education as
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independent variables. The residual of the fit is the new value associate to each
region. This was done for both patients (AD+MCI) and control (CN) groups
separately. Then we discarded white matter, ventricular and cerebellar regions,
remaining with 82 regions. we averaged SUVr of each region from both hemi-
spheres; among the 41 remained regions, we averaged together the ones belonging
to the same lobe/the same subcortical region. We selected 11 macro-regions, i.e.
frontal, temporal, parietal, cingulate, thalamus, caudate, putamen, pallidum,
hippocampus, amygdala, accumbens, and averaged together all the values of
ROIs mapped to the same macro-region. The macro–region definition was done
to reduce computational expenses and aid interpretability of the resulting MP
parameters. Demographic and clinical details are shown in Table 3. We split the
data set in two parts: the D1 data set contains all the longitudinal data for each
subject up to the second-to-last time points. The remaining time–points were
included in a second data set D2. Subjects with one measurement only were
included in D1. Data set D1 includes 1651 longitudinal data of 1091 subjects;
D2 contains 731 cross-sectional data. We run the models on D1, estimating MP
dynamics, GP parameters and individual time–shifts, and used D2 to validate
model predictions.
Group CN MCI AD
N (female) 369 (194) 526 (229) 195 (79)
age (std) 73.5 (6.0) 72.0 (7.5) 73.8 (7.7)
years education (std) 16.5 (2.6) 16.1 (2.7) 15.8 (2.7)
APOE4 + 102 244 129
ADAS13 (std) 9.1 (4.6) 14.9 (6.9) 31.3 (9.6)
FAQ (std) 0.3 (1.3) 2.7 (4.0) 14.1 (7.1)
MMSE(std) 29.0 (1.2) 28.0 (1.8) 22.6 (3.2)
RAVLT learning (std) 5.9 (2.4) 4.7 (2.6) 1.9 (1.8)
Table 3. Baseline socio demographic and clinical information the study cohort
(1090 subjects for 2380 time–points). ADAS13: Alzheimer’s Disease Assessment Scale-
cognitive subscale, 13 items; FAQ: Functional Assessment Questionnaire; RAVLT learn-
ing: Rey Auditory Verbal Learning Test, learning item.
HCP data. Data used in the preparation of this work were obtained from the
MGH-USC Human Connectome Project database. We collected 3D T1w and
DTI of 24 age and gender–matched subjects. The pipeline for structural connec-
tome generation is described in [5]. We averaged the 24 connectomes together
and obtained an average young, healthy connectome. Finally, we averaged to-
gether the regions belonging to the same lobe or subcortical area (to obtain 11
macro–region) and we set to 0 all the weights below the average weights across
nodes, and to 1 the weight above. This last step was performed in order to
remove the weak connections.
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4.2 Estimated long term dynamics.
We analyzed the AV45–PET data with two different models of MP kinetics: the
ACP model of equation (2) - which has non–linear and time–varying dynam-
ics, and a full diffusive model. The diffusion dynamics were prescribed by the
system c˙(t) = Bc(t), where the coefficients bij of B are estimated (along with
individual time parameters) with our framework. Figure 3A) shows the long
term trajectories estimated with both models, for four regions. Full results are
in the Supplementary Material. Figure 3B) shows the time associated to each
regional trajectory at which maximal separation between “Cognitively Normal”
and “Alzheimer’s disease” subjects was measured. The time distribution is in-
ferred from the trajectory distribution associated to each region. The dynamics
and orderings of ACP and diffusion provide plausible description of the patholog-
ical evolution of amyloid deposition, compatible with previous findings in histo
pathological and imaging studies in AD [15,16].
4.3 Predictions performances of the models.
Figure 3C) shows the estimated vector fields for the relative dynamics of the
frontal and parietal lobes. This vector field is obtained by integrating the dy-
namical system estimated for respectively ACP and diffusion models. Therefore
it does not correspond to extrapolation of the curves in Figure 3A). Here the
other biomarkers are set constant to their mean values. We can appreciate the
non–linear dynamics of the ACP model, as well as the linear dynamics of the dif-
fusive model. The resulting vector fields provide a tool for interpreting and com-
paring mechanistic hypotheses. Indeed, Figure 3C) shows that the ACP model
estimates an initial fast propagation, which slows down with time. The opposite
behaviour is observed by analyzing the dynamics of the diffusion model, with
an acceleration in the propagation along with the progression. This behaviour
is unlikely to reproduce real–case scenarios, where amyloid aggregation eventu-
ally slows down and does not accumulates indefinitely. This result points to the
higher biological plausibility of the proposed ACP model. For each subject in
D1 with follow-up measurements in D2, we computed the streamline associated
with their individual dynamics (in the whole 11-D space), and estimated the
values of each biomarker at the corresponding follow-up time. We computed the
RMSE for each estimate, and bootstrapped over the MP dynamic parameters
200 times, obtaining RMSE distributions (Table 4).
4.4 Misfolded proteins propagation pathways.
Figure 4 shows the connectomes where the edges’ colors are set to be proportional
to the values of the estimated MP parameters for the ACP model (plot on the
left hemisphere), or to the values of the propagation parameters for the diffusive
model (plot on the right hemisphere). The parameters were normalized to [0, 1]
to aid comparison. The paths appear to be different for the two models and the
ACP model seems to better describe the frontal–posterior pathway known to
characterize amyloid deposition in AD [15,16].
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Fig. 3. A): estimated long term trajectories and individual short term measurements
for 4 regions of interest: frontal lobe, parietal lobe, caudate and pallidum, for the
two models. B): ordering derived from the trajectories. Regions visualized in A) are
highlighted. C): streamlines of the 2D fields in the {Frontal, Parietal} plane.
frontal temporal parietal cingulate
ACP 0.21(0.16) 0.18(0.14) 0.20(0.16) 0.20(0.15)
diffusion 0.25(0.18) 0.25(0.17) 0.22(0.19) 0.24(0.18)
thalamus caudate putamen pallidum hippo amygdala accumbens
ACP 0.12(0.09) 0.16(0.12) 0.16(0.13) 0.13(0.10) 0.12(0.09) 0.12(0.10) 0.21(0.15)
diffusion 0.11(0.08) 0.17(0.13) 0.17(0.13) 0.17(0.13) 0.12(0.09) 0.11(0.09) 0.24(0.19)
Table 4. RMSE (mean, sd) for the ACP and the diffusion models estimates. The ACP
model generally provides predictions closer to the observed follow-up values.
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Fig. 4. Coronal and axial views of connectomes with edges’ colors proportional to
the values of the estimated propagation parameters for either the ACP model (left
hemisphere) and the diffusion model (right hemisphere).
5 Discussion
We presented a spatio–temporal model of MP dynamics over brain networks.
The model is based on the joint estimation of long term MP dynamics and time
reparametrization of individuals observations, and is expressed within a GP re-
gression setting, where constraints on the MP dynamics are imposed through
non–linear dynamical systems, which account for accumulation, clearance and
propagation of MP. Experiments on simulated data show that our model ac-
curately recovers prescribed rates along graph dynamics and precisely recon-
structs the underlying progression. When applied to AV45-PET brain imaging
data our model allows the bio-mechanical interpretation of amyloid deposition
in Alzheimer’s disease, leading to plausible simulations of MP propagation, and
achieving accurate predictions of individual MP deposition in unseen data.
The method has some limitations: first of all, structural connectome esti-
mation using tractography is known to be prone to false positive and negative
connections. Nevertheless, here we take an average connectome over multiple
young and healthy subjects, which we believe provides a reasonable anatomical
reference. Another limitation of the model is that it assumes that all subjects
follow the same disease progression pattern, which might not be the case in
heterogeneous data sets such as ADNI.
The ideas we propose here extend to a much larger range of diseases and
alternative models of propagation, such as propagation via functional networks
[6,8], or different kind of tractography to represent intra– and extra–axonal prop-
agation [5,7].
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Supplementary Material
Details on the implementation
The optimization is performed with stochastic gradient descent with adaptive
moment estimation (Adam), through the alternate optimization of i) the ap-
proximated posterior over W , the likelihood parameters for the GP and for the
random effect, ii) the individual time–shifts parameters, and iii) the approxi-
mated posterior over the MP parameters and the likelihood parameters of the
constraints. Also, for the MP parameters scheme, we split optimization over k¯ij
and k¯t, and over ηi and γi. This is done to reduce the variability of their gradi-
ents, as such parameters have values in different ranges. Further, we first run the
optimization scheme for estimating values of the two brain–level parameters η
and γ, and then estimate ηi and γi using as starting points the estimated values
of η and γ and lowering the learning rate.
Simulation on single–subject
Figure 5 shows examples of long term trajectories that is possible to obtain by
varying the MP parameters of the ACP model, on a specified time interval, for
a two–region problem. Figure 6A) and 6B) show the results of the fit for the
Fig. 5. Examples of (noisy) long–term trajectories obtained by varying the MP pa-
rameters and the noise, on a time interval [0,15].
example data in Figure 2 top left in term of the concentration evolution over
time of the MP dynamics and of the MP parameter.
In order to evaluate the accuracy of the model in reconstructing the param-
eters for increasing number of regions, we generated other five two-dimensional
16 Authors Suppressed Due to Excessive Length
Fig. 6. Results for example data in Figure 5(a). A) data as circles and estimated
dynamics as lines. B) estimated distribution of kij , kt, γ and η (2-σ shown here), and
their ground truth values as vertical black lines.
problems varying the MP parameters and the noise (as in Figure 5), and re-
peated the procedure for increasing number of regions: 3, 5, 11 and 42. Table 5
shows the distributions of the rooted mean square errors (RMSEs) for each MP
parameter and for the GP parameters (estimated VS ground truth parameters),
at increasing number of regions. We note that the RMSEs are always close to
zero, with the smallest error consistently on kt and the biggest on η or γ.
N=2 N=3 N=11 N=42
k¯ij 1.4% 1.4% 4.4% 4.4%
k¯t 0.3% 0.3% 0.1% 0.1%
γ 11.3% 11.5% 18.0% 23.2%
η 14.7% 16.9% 24.2% 23.0%
Data fit 7.4% 8.4% 8.5% 10.2%
Table 5. RMSE results for dynamical parameters and GP fit estimates for the ACP
model. The errors are expressed, in percentage, relatively to the ground truth param-
eters.
Full results for the real data scenario
Figure 7 shows the estimated long term trajectories for all the 11 macro-regions,
in the time interval [-10, 15], for both the models.
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Fig. 7. estimated long term trajectories for the ACP (left) and the diffusion (right)
models.
